Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review

Αngeliki Andrikopoulou; Oraianthi Fiste; Michalis Liontos; Meletios A Dimopoulos; Flora Zagouri

doi:10.3390/cancers13030465

Abstract

1 min read

AI treatment-induced musculoskeletal syndrome is an adverse event affecting over one-third (20-47%) of postmenopausal patients treated with AIs that often leads to treatment discontinuation. Data from RCTs provide evidence that the incidence of musculoskeletal symptoms is relatively decreased upon CDK4/6 inhibitor administration. CDK4/6 inhibitors may provide a protective role against AIMSS development.

Related publications

Article2023

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting

Efthymia Skafida, Αngeliki Andrikopoulou, Evangelos Terpos, Christos Markellos, Savvina Moustafa, Dimitrios Pectasides, Meletios A Dimopoulos, Flora Zagouri, Dimitrios Vassilopoulos

Article2021

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience

Αngeliki Andrikopoulou, Oraianthi Fiste, Kleoniki Apostolidou, Efthymia Skafida, Christos Markellos, Michalis Liontos, Anastasios Kyriazoglou, Meletios A Dimopoulos, Flora Zagouri

Article2019

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Shatha AbuHammad, Carleen Cullinane, Claire Martin, Zoe Bacolas, Teresa Ward, Huiqin Chen, Alison Slater, Kerry Ardley, Laura Kirby, Keefe T. Chan, Natalie Brajanovski, Lorey Smith, Aparna D. Rao, Emily J. Lelliott, Margarete Kleinschmidt, Ismael A. Vergara, Anthony T. Papenfuss, Peter K. H. Lau, Prerana Ghosh, Sue Haupt, Ygal Haupt, Elaine Sanij, Gretchen Poortinga, Richard B. Pearson,

Article2023

CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence.

Oraianthi Fiste, Michalis Liontos, Maria Gavriatopoulou, Constantine Dimitrakakis, George Evangelou, Vasiliki Nikolaidou, Ηλίας Κοττέας, Kostas Syrigos, Meletios A Dimopoulos, Flora Zagouri

Article2020

Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

James R. Whittle, François Vaillant, Elliot Surgenor, Antonia N. Policheni, Göknur Giner, Bianca D. Capaldo, Huei-Rong Chen, He K. Liu, Johanna F. Dekkers, Norman Sachs, Hans Clevers, Andrew Fellowes, Thomas Green, Hui-Ling Xu, Stephen B. Fox, Marco J. Herold, Gordon K. Smyth, Daniel H.D. Gray, Jane E. Visvader, Geoffrey J. Lindeman